Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy

Desheng Wang, Weridong Jia, Zhiming Wang, Tianfu Wen, Wei Ding, Feng Xia, Ling Zhang, Feixiang Wu, Tao Peng, Bin Liu, Cuncai Zhou, Qichang Zheng, Xiongying Miao, Junping Peng, Zhiyong Huang, Kefeng Dou, Desheng Wang, Weridong Jia, Zhiming Wang, Tianfu Wen, Wei Ding, Feng Xia, Ling Zhang, Feixiang Wu, Tao Peng, Bin Liu, Cuncai Zhou, Qichang Zheng, Xiongying Miao, Junping Peng, Zhiyong Huang, Kefeng Dou

Abstract

Background: There is no guideline recommendation for preventing hepatocellular carcinoma (HCC) recurrence after hepatic resection. Moreover, an unmet need exists on the effectiveness of sorafenib therapy in recurrent HCC. Purpose: We therefore assessed the efficacy and safety of sorafenib in Chinese HCC patients with high risk of recurrence. Patients and methods: Data were collected retrospectively from 15 Chinese research centers from January 1, 2012 to November 15, 2013, by chart reviews of patients with moderate-advanced HCC who received hepatic carcinectomy. The primary end point was recurrence-free survival rate at 1 year in patients with a high recurrence risk. Secondary end points included 1-year survival rate, time to recurrence and safety assessment. Results: A total of 209 high-risk patients (sorafenib, n=98; control, n=111) who underwent carcinectomy were analyzed. There was no significant difference in the proportion of patients with recurrence-free survival at 1 year between the sorafenib and control (70.43% vs 68.90%: χ2=0.007, P=0.934). One-year survival rate was significantly higher with sorafenib than observed with control (95.5% vs 83.35%; χ2=7.441, P=0.006). Time to recurrence between sorafenib and control groups was similar. Incidences of all the adverse events (AEs) were similar in both the groups and transaminase elevation was most common in both groups (20.37% vs 24.79%). Thrombocytopenia incidence was significantly lower with the sorafenib group than with control (1.85% vs 9.40%; P=0.015). Conclusion: Sorafenib may be considered as a feasible option in the treatment of HCC recurrence.

Keywords: Chinese; carcinectomy; hepatocellular carcinoma; recurrence; sorafenib; survival.

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
One-year recurrence-free survival rates.
Figure 2
Figure 2
One-year survival rate.

References

    1. Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int Off J Int Assoc Study Liver. 2015;35:2155–2166. doi:10.1111/liv.12818
    1. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424–432. doi:10.1038/ncponc0844
    1. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S80–S89. doi:10.1016/j.jceh.2014.05.004
    1. Chok KSH, Chan SC, Cheung TT, et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World J Surg. 2011;35:2058–2062. doi:10.1007/s00268-011-1146-z
    1. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994;106:1618–1624. doi:10.1016/0016-5085(94)90419-7
    1. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatol Baltim Md. 1997;25:87–92. doi:10.1053/jhep.1997.v25.pm0008985270
    1. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–235. doi:10.1097/01.sla.0000197706.21803.a1
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857
    1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. doi:10.1016/S0140-6736(18)30207-1
    1. Vitale A, Boccagni P, Kertusha X, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc. 2012;44:1989–1991. doi:10.1016/j.transproceed.2012.06.046
    1. Sotiropoulos GC, Nowak KW, Fouzas I, et al. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Transplant Proc. 2012;44:2754–2756. doi:10.1016/j.transproceed.2012.09.022
    1. Bhoori S, Toffanin S, Sposito C, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol. 2010;52:771–775. doi:10.1016/j.jhep.2010.01.025
    1. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725–733. doi:10.1016/j.jhep.2009.03.028
    1. Yoon DH, Ryoo B-Y, Ryu M-H, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol. 2010;40:768–773. doi:10.1093/jjco/hyq055
    1. Saab S, McTigue M, Finn RS, Busuttil RW. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant Off J Middle East Soc Organ Transplant. 2010;8:307–313.
    1. Wang S-N, Chuang S-C, Lee K-T. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study: sorafenib prevents early HCC recurrence. Hepatol Res. 2014;44:523–531. doi:10.1111/hepr.12159
    1. Pfiffer TE, Seehofer D, Nicolaou A, et al. Relapse of hepatocellular carcinoma (HCC) after liver transplantation (LT): a single-center analysis on 139 patients in the sorafinib era. J Clin Oncol. 2010;28:4088. doi:10.1200/jco.2010.28.15_suppl.4088
    1. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354. doi:10.1016/S1470-2045(15)00198-9
    1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in. J Hepatol. 2008;48:S20–S37. doi:10.1016/j.jhep.2008.01.022
    1. Alsina AE, Makris A, Nenos V, et al. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. Am Surg. 2014;80:680–684.
    1. Ning Chong CC, San Lai PB. Treatment strategy for recurrent hepatocellular carcinoma In: Julianov A, editor. Liver Tumors. London: InTech; 2012: Chapter 8.
    1. De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2014;46:241–244. doi:10.1016/j.transproceed.2013.10.035
    1. Takahara T, Nitta H, Hasegawa Y, et al. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation–interactions between calcineurin inhibitor: two case reports. Transplant Proc. 2011;43:2800–2805. doi:10.1016/j.transproceed.2011.06.063
    1. Yokoyama I, Carr B, Saitsu H, et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer. 1991;68:2095–2100.
    1. Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer. 2011;42:50–53. doi:10.1007/s12029-010-9196-2
    1. Feun LG, Levi D, Moon J, et al. Tzakis A Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation. J Clin Oncol. 2009;27(15):e15579.
    1. Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant. 2014;(2014):913634. doi:10.1155/2014/913634
    1. Yokoo H, Kamiyama T, Kakisaka T, et al. [Efficacy of sorafenib for extrahepatic recurrence of hepatocellular carcinoma after liver resection]. Gan To Kagaku Ryoho. 2015;42:1497–1499.
    1. Weinmann A, Niederle IM, Koch S, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2012;44:432–437. doi:10.1016/j.dld.2011.12.009
    1. Clavien P-A, Lesurtel M, Bossuyt PMM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–e22. doi:10.1016/S1470-2045(11)70175-9
    1. Kim HY, Park J-W, Nam B-H, et al. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011;26:1612–1618. doi:10.1111/j.1440-1746.2011.06751.x
    1. Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol. 2013;59:59–66. doi:10.1016/j.jhep.2013.02.026
    1. Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Biosci Trends. 2014;8:333–338. doi:10.5582/bst.2014.01120
    1. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858. doi:10.1158/0008-5472.CAN-06-1377
    1. Wei J, Meng F, Qu K, et al. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin. 2015;36:241–251. doi:10.1038/aps.2014.122
    1. Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biol Targets Ther. 2008;2:779–788. doi:10.2147/BTT.S3410
    1. Heqing Y, Bin L, Xuemei Y, Linfa L. The role and mechanism of autophagy in sorafenib targeted cancer therapy. Crit Rev Oncol Hematol. 2016;100:137–140. doi:10.1016/j.critrevonc.2016.02.006
    1. Kitade H, Yanagida H, Yokoigawa N, et al. [Two patients with recurrence of hepatocellular carcinoma after liver resection who achieved long-term stable disease with small doses of sorafenib therapy]. Gan To Kagaku Ryoho. 2015;42:863–865.
    1. Feng Y-X, Wang T, Deng Y-Z, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatol Baltim Md. 2011;53:483–492. doi:10.1002/hep.24075

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren